Webcast Hemostemix Inc. (OTCQB: HMTXF | TSXV: HEM)

Hemostemix Inc. (OTCQB: HMTXF | TSXV: HEM)

 · America/New_York

About This Webcast

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is commercializing VesCell™ an investigational autologous stem cell therapy. VesCell™ is derived from a patient's own blood and evaluated through structured clinical research. Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, and appears clinically relevant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI diabetes-based patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com. Book a Meeting With This Company (opens in a new tab) Industry: Regenerative cell therapy View OTC Markets Profile for this company (opens in a new tab) Visit Investor Relations Website for this company (opens in a new tab) Connect on LinkedIn with this company (opens in a new tab) Follow on X this company (opens in a new tab)

Speakers

Thomas Smeenk

Thomas Smeenk

President & CEO, Co-Founder , Hemostemix Inc.

A chief executive who structures, negotiates and has closed eight figure contracts. A dynamic business development and management team leader who delivers timely profitable results domestically and internationally. An adept communicator who succeeds at collaborative and interpersonal relationships with management, prospects, clients and suppliers.